🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are on the rise globally, with data suggesting more than 82 million instances annually. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The WHO has listed it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines a dual-drug approach. The trial included over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Medical professionals on the front lines have expressed positive views. Access to a easy-to-administer therapy like this is described as a "revolutionary step" for public health efforts. This is considered vital to reduce the burden of the infection for people and to prevent the spread of untreatable gonorrhoea worldwide.